http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6330415-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_617a9b6a38ad87fdf464136d1e5ad460
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
filingDate 1986-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f33bc13c804395286a737c413c8ac70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71957a3392b729fb000974d80f616254
publicationDate 1988-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S6330415-A
titleOfInvention Antioxidation agent
abstract PURPOSE: To provide an antioxidation agent containing paeoniflorin as an active component and effective in preventing the oxidation by active oxygen. n CONSTITUTION: The objective agent contains paeoniflorin of formula as an active component. Paeoniflorin is a compound existing in SHAKUYAKU (root of Paeonia albiflora) known as a Chinese herb drug. The agent is effective as a remedy for arteriosclerosis, myocardial infarction, cerebral apoplexy, cerebral hemorrhage, cerebral infarction, cerebral thrombosis, cataract, inflammation, autoimmune diseases, etc., and is administered preferably at a rate of 150W300mg daily for adult as an oral drug or 3W60mg daily for adult as a parenteral drug. n COPYRIGHT: (C)1988,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100732886-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100769580-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103977387-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008505128-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005107698-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1767210-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1767210-A4
priorityDate 1986-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID442534
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226857855
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID977
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID35924
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523291
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419508951
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID35924

Total number of triples: 40.